Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion - 5 Nov 2021

Oñate-Ocaña Luis F, Ponce-Martínez Mayra, Taja-Chayeb Lucia, Gutiérrez-Hernández Olga, Avilés-Salas Alejandro, Cantú-de-León David, Dueñas-González Alfonso, Candelaria-Hernández Myrna

Abstract excerpt

BACKGROUND: Novel prognostic factors in patients with diffuse large B-cell lymphoma (DLBCL) are required in the era of Rituximab. OBJECTIVE: The objective of the study was to study the prognostic impact of exon-16 enhancer-of-zeste homolog-2 (EZH2) mutations in patients with DLBCL. METHODS: In a cohort of patients with DLBCL treated between 2015 and 2017, we analyzed the presence of EZH2 mutations and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Rituximab

Source

Identifiers

PMID: 34044429
DOI: 10.24875/RIC.21000070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.PMID 34044429Read ↗

Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?Semantic proximity Read ↗

Mutations at Codon 641 of Exon 16 of EZH2 in Circulating Tumor DNA: A Biomarker for Relapse in Patients With Diffuse Large B-cell Lymphoma Treated With the R-CHOP Scheme.Semantic proximity Read ↗

ct-DNA is useful to diagnose mutations at codon 641 of exon 16 of EZH2, which is a biomarker for relapse in patients with Diffuse Large B-cell Lymphoma treated with the R-CHOP scheme.Semantic proximity Read ↗

Characterizing the Mutational Landscape of Diffuse Large B-Cell Lymphoma in a Prospective Cohort of Mexican Patients.Semantic proximity Read ↗

The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review.Semantic proximity Read ↗

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity Read ↗

Clinical Expression, Prognosis and Immune Infiltration of SUV39H1 in Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.Semantic proximity Read ↗

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read ↗

EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.Semantic proximity Read ↗

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphomaSemantic proximity Read ↗

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.